BEOVU 120mg/ml Price

Overview

Welcome to Dwaey, specifically on BEOVU 120mg/ml page.
This medicine contains an important and useful components, as it consists of
Brolucizumabis available in the market in concentration

Name

Bleomycin

Precaution

Before initiating **Bleomycin**, it is crucial to consult with a healthcare provider due to potential risks and interactions with pre-existing conditions. Some key precautions include: - **Pulmonary Toxicity**: Bleomycin is known for its potential to cause **pulmonary toxicity**, including **pulmonary fibrosis**, which can lead to severe lung damage. Baseline pulmonary function tests should be conducted before starting treatment, and lung function should be monitored throughout therapy, especially in older patients or those with pre-existing lung conditions such as **COPD** or asthma. - **Renal Impairment**: Bleomycin is partially excreted through the kidneys, so patients with **renal impairment** may be at increased risk for toxicity. A lower dose or extended dosing intervals may be necessary for these patients. - **Myelosuppression**: Bleomycin can cause **bone marrow suppression**, leading to reduced blood cell counts, particularly in patients undergoing concurrent chemotherapy. Regular monitoring of blood counts is important during treatment. - **Fever and Chills**: A common side effect of Bleomycin is fever and chills, which may be associated with an infusion reaction. Caution is required when administering the drug in an inpatient setting where the patient can be observed closely. - **Pregnancy and Breastfeeding**: Bleomycin is categorized as a **Category D** drug for pregnancy, indicating potential risks to the fetus. It should only be used during pregnancy if the benefits outweigh the risks. It is unknown whether Bleomycin is excreted in breast milk, but it is recommended to avoid breastfeeding during therapy.

Indication

Bleomycin is primarily used in the treatment of various cancers, including: - **Testicular Cancer**: Bleomycin is part of combination chemotherapy regimens for the treatment of **testicular cancer**, particularly in **non-seminomatous germ cell tumors**. - **Hodgkin’s Lymphoma**: It is used in combination chemotherapy protocols (e.g., **ABVD** regimen) for the treatment of **Hodgkin’s lymphoma**. - **Non-Hodgkin’s Lymphoma**: Similar to Hodgkin’s lymphoma, Bleomycin is also employed in the treatment of **non-Hodgkin’s lymphoma**, as part of multi-drug chemotherapy regimens. - **Squamous Cell Carcinomas**: Bleomycin is effective against certain **head and neck cancers**, including **squamous cell carcinoma** of the **lung**, **skin**, and **cervix**. - **Kaposi’s Sarcoma**: In combination with other chemotherapy drugs, Bleomycin is sometimes used for **Kaposi’s sarcoma** in patients with HIV/AIDS. - **Pleural Effusion**: Bleomycin has been used off-label for **pleural effusion**, including **malignant pleural effusion**, as it can help in reducing the size of fluid collections.

Contra indication

Bleomycin should be avoided in certain situations, including: - **Severe Pulmonary Disease**: Patients with **severe pulmonary disease**, such as advanced **pulmonary fibrosis** or **COPD**, should not receive Bleomycin due to the risk of exacerbating lung toxicity. - **Severe Renal Impairment**: Bleomycin is contraindicated in patients with **severe renal impairment**, as kidney dysfunction can lead to a build-up of the drug and increase the risk of toxic effects. - **Hypersensitivity**: Bleomycin is contraindicated in patients with a known **hypersensitivity** or allergic reaction to the drug. Symptoms may include rash, fever, or difficulty breathing. - **Pregnancy**: Bleomycin is classified as **Category D** for pregnancy, meaning it has the potential to harm the fetus and should be avoided unless absolutely necessary. It is contraindicated during pregnancy unless the potential benefit outweighs the risk. - **Breastfeeding**: Due to the potential unknown risks to the infant, Bleomycin should be avoided during breastfeeding.

Side Effect

Common and severe side effects of **Bleomycin** include: - **Common Side Effects**: - **Fever and Chills**: Commonly occur during or shortly after infusion. - **Nausea and Vomiting**: These symptoms are often seen in chemotherapy regimens involving Bleomycin, although they are typically mild to moderate. - **Fatigue**: Due to the nature of chemotherapy, many patients experience significant fatigue during treatment with Bleomycin. - **Mouth Ulcers**: Some patients may develop **oral ulcers** or sores as a result of the treatment. - **Severe Side Effects**: - **Pulmonary Toxicity**: This is the most significant adverse effect of Bleomycin, ranging from **pulmonary fibrosis** to more acute reactions such as **dyspnea (shortness of breath)** and **hypoxia**. - **Hypersensitivity Reactions**: Rarely, patients may develop **severe allergic reactions**, such as anaphylaxis, with symptoms like **rash, swelling**, and **difficulty breathing**. - **Myelosuppression**: Bleomycin can lead to a decrease in blood cell production, causing **anemia**, **leukopenia**, and **thrombocytopenia**, which can increase the risk of infection, bleeding, or fatigue. - **Skin Changes**: **Skin pigmentation** changes, including darkening or thickening of the skin, may occur, particularly in patients receiving long-term treatment. - **Liver Dysfunction**: Bleomycin has been associated with **elevated liver enzymes** and hepatotoxicity, which may require dose adjustments or discontinuation.

Pregnancy Category ID

4

Mode of Action

**Bleomycin** works by **interfering with DNA synthesis** and promoting **DNA strand breaks**, which inhibits the replication of cancer cells. This mechanism primarily affects **rapidly dividing cells**, such as cancer cells, by causing **single- and double-strand breaks** in the DNA, leading to cell death. The primary actions include: - **Intercalation**: Bleomycin binds to DNA, inserting itself between the DNA bases, which disrupts the normal DNA structure and function. - **Generation of Free Radicals**: Bleomycin generates highly reactive **free radicals** that further damage the DNA, leading to cell death. These radicals can cause severe damage to cancer cells, especially in the **G2 phase** of the cell cycle. - **Inhibition of DNA Repair**: The drug impairs the cell’s ability to repair DNA damage, further increasing the rate of cancer cell death. - **Selective Toxicity**: Bleomycin has a selective effect on rapidly dividing cells, making it effective against certain cancers but also contributing to toxicity in normal cells, particularly in the lungs.

Interaction

Bleomycin can interact with other medications and substances, which may alter its effectiveness or lead to adverse effects: - **Other Chemotherapy Agents**: Bleomycin may interact with other chemotherapy drugs, such as **cyclophosphamide**, **methotrexate**, or **doxorubicin**, which can increase the risk of **pulmonary toxicity** or **myelosuppression**. - **Radiation Therapy**: When combined with **radiation therapy**, especially if the radiation is targeted to the lungs, Bleomycin can increase the risk of **pulmonary fibrosis**. Close monitoring is essential during such treatment combinations. - **Cisplatin**: Concurrent use of **cisplatin** (another chemotherapy agent) may increase the risk of **nephrotoxicity** (kidney damage), and as both drugs are excreted via the kidneys, dose adjustments may be needed. - **Oxygen Therapy**: High concentrations of **oxygen** during surgery or mechanical ventilation may exacerbate Bleomycin-related **pulmonary toxicity**. Caution should be exercised when administering oxygen to patients on Bleomycin therapy. - **Drugs Affecting the Liver**: As Bleomycin is metabolized by the liver, drugs that affect liver function (such as **hepatic enzyme inducers** or **inhibitors**) may impact the metabolism of Bleomycin, requiring dose adjustments.

Pregnancy Category Note

Information not available

Adult Dose

The dosing of **Bleomycin** depends on the type of cancer being treated and the chemotherapy regimen. Typical dosages include: - **Hodgkin’s Lymphoma**: The usual dose is **10-20 units** via **IV** or **subcutaneous injection** once a week or in a combination with other chemotherapy agents (e.g., ABVD regimen). - **Non-Hodgkin’s Lymphoma**: A typical dose is **10 units** every **2 to 3 weeks** or as part of combination therapy. - **Testicular Cancer**: The usual dose is **30 units** administered weekly as part of combination chemotherapy for **3-4 weeks**. - **Squamous Cell Carcinomas**: Dosage varies, typically between **15-30 units** weekly, depending on the tumor type and response. - **Kaposi’s Sarcoma**: A dose of **10 units** is typically used, administered either subcutaneously or intralesionally depending on the patient's condition.

Child Dose

Bleomycin is not typically used in pediatric populations due to limited data and safety concerns. In some cases, a pediatric oncologist may prescribe Bleomycin off-label for specific cancers, but the dose will be carefully adjusted based on the child's weight, age, and clinical condition.

Renal Dose

Bleomycin should be used with caution in patients with **renal impairment**. For patients with **creatinine clearance < 30 mL/min**, the dose of Bleomycin should be **reduced** and carefully monitored. This is to minimize the risk of **toxicity** due to slower excretion.

Administration

Information not available